Subscribe

Emerging Tools for Assessing Value: Pros and Cons

VBCC - August 2015, Vol 6, No 7 - VBCC Perspectives
Kirby J. Eng, RPh

The emergence of various tools for assessing value or, more to the point, drug costs—both direct and indirect—by leaders within the oncology and hematology community is highly commendable. Those of us on the managed care side of healthcare look forward to practical and meaningful tools in helping patients, pro­viders, employers, and health plans navigate through the complexity of oncology drug therapy and drive better informed decision-making.

The pros of these physician-led initiatives are that we are using leading experts in their chosen field as a basis for coverage decisions and for driving meaningful clinical and financial choices.

The cons are whether these tools will gain widespread recognition and adoption by prescribers, and whether they can keep up with the rapid and ongoing changes that are occurring in the marketplace. Based on these early models, and on organizational commitments, I would say that for now, the pros far outweigh the cons.

Related Items
The NCCN Evidence Blocks and Clinical Practice Guidelines: Identifying Truth
Robert W. Carlson, MD, Al B. Benson III, MD, FACP
VBCC - March 2016, Vol 7, No 2 published on March 21, 2016 in Online First, VBCC Perspectives
The NCCN New Tool to Assess Value Discourages Patients’ Hope
Robert Goldberg, PhD
VBCC - November 2015, Vol 6, No 10 published on November 12, 2015 in VBCC Perspectives
AstraZeneca Commentary on Oncology Value Tools
Diane Sullivan
VBCC - October 2015, Vol 6, No 9 published on October 17, 2015 in VBCC Perspectives
The Role of Oncologists in Defining the Value of Cancer Therapy
Michael Kolodziej, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework a Powerful Tool for Shared Decision-Making
Neil B. Minkoff, MD
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework Promoting Accountability and Transparency
Joseph Morse
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Net Health Benefit: A Palliative Care Regimen Scores Higher than Active Treatment
Pamela Pelizzari, MPH, Bruce Pyenson, FSA, MAAA
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
Addressing the Value of New Cancer Treatment Options Using the ASCO Model
Philip E. Johnson, MS, RPh, FASHP
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
The Missing Elements in Our Value-Based Care Discussions
Kevin Cast
VBCC - August 2015, Vol 6, No 7 published on August 18, 2015 in VBCC Perspectives
ASCO’s Value Framework Abandons the Hippocratic Oath
Robert Goldberg, PhD
VBCC - July 2015, Vol 6, No 6 published on July 21, 2015 in VBCC Perspectives
Last modified: August 18, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology